Company: STAA
Filing Date: 2025-08-29
Form Type: PREM14A
Source: 0001193125-25-192889
Chunk: 66

Company: STAAR SURGICAL CO
Filing Date: 2025-08-29
Form: PREM14A
Chunk 66
---
 that Alcon was interested in acquiring all of the outstanding shares of STAAR common stock, and that while similar deals had been completed at a 25%
to 30% premium, he recognized that STAAR would expect a higher premium. On June 26, 2025, the trading price of STAAR common stock closed at $16.83 per share. Mr. Endicott indicated he expected a prompt response from STAAR because Alcon was
considering other strategic options that could potentially preclude a transaction with STAAR. Mr. Farrell responded that he would bring any proposal provided by Alcon to the Board for consideration. Following the meeting, Mr. Farrell conveyed
the substance of his discussions with Mr. Endicott to the Board.

On July 6, 2025, the Board held a meeting to discuss a potential
response to Alcon with members of STAAR’s management and representatives of Citi in attendance. Representatives of Citi reviewed their preliminary financial analysis of STAAR with the Board. STAAR’s management discussed preliminary
financial analyses it had conducted and indicated it would prepare multi-year financial projections for the Board’s consideration at a future meeting. Management noted that STAAR’s expense profile was improved due to the reductions in
operational costs, but that there remained uncertainty regarding the timing and durability of a recovery in refractive procedure volumes in China, which would impact revenue growth scenarios. In addition, the Board considered additional risks and
opportunities that could affect STAAR’s standalone business plan, including competitive threats, a potential trade war and related tariff risks, and the potential for price controls in China. The Board then considered whether to solicit
indications of interest from other third parties for a potential transaction with STAAR. Representatives of Citi reviewed the likely universe of potential buyers and provided their views as to the potential challenges such buyers would face. Among
other things, the Board considered whether a higher value could be obtained for STAAR stockholders from a third party other than Alcon and whether increased competition could result in more attractive pricing or other improved terms for STAAR from
Alcon, as well as potential risks and disruption that could result from exploratory outreaches and potential market rumors, and the terms that could be included in transaction agreement to enable STAAR to achieve the highest

-41-

value for its stockholders. The Board also discussed how, following the market rumors in July 2024 that STAAR was attracting takeover interest, no potential buyers had approached STAAR. Following